Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,058,000 | 2,175,000 | 2,165,000 | 2,045,000 | 2,436,000 |
| Receivables | 4,471,000 | 4,253,000 | 4,529,000 | 4,046,000 | 4,488,000 |
| Inventories | 4,049,000 | 4,012,000 | 3,818,000 | 4,167,000 | 4,362,000 |
| Other current assets | 534,000 | 947,000 | 986,000 | 830,000 | 514,000 |
| TOTAL | $12,164,000 | $12,451,000 | $12,573,000 | $12,154,000 | $12,822,000 |
| Non-Current Assets | |||||
| PPE Net | 5,740,000 | 5,932,000 | 5,982,000 | 6,040,000 | 6,127,000 |
| Intangibles | 25,537,000 | 27,102,000 | 27,506,000 | 28,011,000 | 28,541,000 |
| Other Non-Current Assets | 2,490,000 | 1,573,000 | 1,606,000 | 1,647,000 | 1,706,000 |
| TOTAL | $33,767,000 | $34,607,000 | $35,094,000 | $35,698,000 | $36,374,000 |
| Total Assets | $45,932,000 | $47,059,000 | $47,666,000 | $47,851,000 | $49,195,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,719,000 | 2,077,000 | 1,426,000 | 2,709,000 | 3,530,000 |
| Accounts payable and accrued liabilities | 1,901,000 | 1,750,000 | 1,686,000 | 1,514,000 | 1,551,000 |
| Accrued Expenses | 2,579,000 | 3,078,000 | 2,771,000 | 2,590,000 | 2,318,000 |
| Other current liabilities | 4,796,000 | 4,707,000 | 5,144,000 | 5,011,000 | 5,291,000 |
| TOTAL | $10,996,000 | $11,613,000 | $11,027,000 | $11,825,000 | $12,691,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 20,363,000 | 20,840,000 | 21,617,000 | 21,037,000 | 21,602,000 |
| Other Non-Current Liabilities | 4,240,000 | 3,678,000 | 2,987,000 | 2,617,000 | 2,645,000 |
| TOTAL | $25,108,000 | $25,187,000 | $25,395,000 | $24,575,000 | $25,193,000 |
| Total Liabilities | $36,103,000 | $36,799,000 | $36,422,000 | $36,400,000 | $37,884,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,110,565 | 1,110,352 | 1,103,330 | 1,103,007 | 1,102,886 |
| Common Shares | 57,000 | 57,000 | 57,000 | 57,000 | 57,000 |
| Retained earnings | -11,716,000 | -11,484,000 | -10,529,000 | -10,370,000 | -10,662,000 |
| Other shareholders' equity | -2,010,000 | -1,772,000 | -1,717,000 | -1,637,000 | -1,459,000 |
| TOTAL | $9,828,000 | $10,260,000 | $11,244,000 | $11,451,000 | $11,311,000 |
| Total Liabilities And Equity | $45,931,000 | $47,059,000 | $47,666,000 | $47,851,000 | $49,195,000 |